Metavia Reports Additional Positive Top-Line Results From the Mad Part 2 of Its Phase 1 Study of Da-1726, a Novel 3:1 Ratio Glp-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-in-Class Potential

THOMSON REUTERS
22 Apr

Metavia Reports Additional Positive Top-Line Results From the Mad Part 2 of Its Phase 1 Study of Da-1726, a Novel 3:1 Ratio Glp-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-in-Class Potential

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10